Receive our newsletter – data, insights and analysis delivered to you

US accounts for 20.5% share of global clinical trial activity in 2020

The US has accounted for a 20.5% share of the global clinical trials activity in 2020, registering a decrease when compared with the last ten-year average of a 25.7% share, according to GlobalData.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Industry sponsored trials outnumber non-industry sponsored trials in US

Industry sponsored trials held a 64.5% share of all the clinical trials in the US in 2020, when compared with the ten-year average of 63.2%. Non-industry sponsored trials accounted for a 35.5% share in 2020 as against the average of 36.8% in the last ten years.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Top therapy areas for industry sponsored clinical trials in US

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

Oncology was the leading therapy area for industry sponsored clinical trials in the US in 2020 with a 35.0% share, as against a five-year average of 36.3% and a ten-year average of 32.9%.

Infectious Disease held an 18.5% share in 2020, over a five-year average of 8.3% and a ten-year average of 10.0%.

Central Nervous System held a 12.9% share in 2020, compared to a five-year average of 15.4% and a ten-year average of 15.9%. Respiratory held a 7.6% share in 2020, as against a five-year average of 4.2% and a ten-year average of 4.6%.

Immunology held a 5.7% share, over a five-year average of 6.3% and a ten-year average of 6.5%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Top therapy areas for non-industry sponsored clinical trials in US

Oncology was the leading therapy area for non-industry sponsored clinical trials in the US in 2020 with a 31.1% share, as against a five-year average of 31.1% and a ten-year average of 31.4%.

Central Nervous System held a 24.3% share in 2020, over a five-year average of 29.6% and a ten-year average of 28.5%.

Infectious Disease held a 20.0% share in 2020, compared to a five-year average of 8.9% and a ten-year average of 9.1%. Cardiovascular held a 7.2% share in 2020, as against a five-year average of 8.7% and a ten-year average of 8.6%.

Respiratory held a 5.7% share, over a five-year average of 4.0% and a ten-year average of 4.1%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Phase II trials lead industry sponsored clinical trials in US in 2020

Phase II trials held a 43.5% share of industry sponsored clinical trials in the US in 2020, over a five-year average of 43.1% and a ten-year average of 41.0%.

Phase I trials held a 26.8% share in 2020, as against a five-year average of 26.1% and a ten-year average of 27.1%. Phase III trials held a 23.3% share in 2020, compared to a five-year average of 23.3% and a ten-year average of 22.8%.

Phase IV trials held a 6.3% share in 2020, over a five-year average of 7.6% and a ten-year average of 9.0%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Phase II trials lead non-industry sponsored clinical trials in US in 2020

Phase II trials held a 49.6% share of non-industry sponsored clinical trials in the US in 2020, over a five-year average of 47.7% and a ten-year average of 49.4%.

Phase I trials held a 22.5% share in 2020, as against a five-year average of 23.7% and a ten-year average of 23.1%. Phase IV trials held a 16.8% share, compared to a five-year average of 19.9% and a ten-year average of 18.5%.

Phase III held an 11.1% share in 2020, over a five-year average of 8.7% and a ten-year average of 9.0%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Methodology:

The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU